Anemia Drugs Market by Technology, Share, Size, Segmentation, Revenue Analysis Forecast 2028
Global Anemia Drugs Market – Overview
Anemia is characterized by weakness, shortness of breath and a general
tiredness due to a decrease in the total amount of red blood cells (RBCs) or
haemoglobin in the blood. The lowered haemoglobin results in a lowered ability
of the blood to carry oxygen. There are three main types of anaemia, i.e. due
to blood loss, due to decreased or faulty red blood cell production and due to
increased red blood cell breakdown. Anaemia affects a quarter of people of the
world and of the different types of anaemia iron deficiency anaemia comprises
of the largest number of people affected, about 1 billion and resulting in
approximately 215,000 deaths each year. Anaemia is also more common in females
than males. It also has a greater propensity to affect children, pregnant and lactating
women and the elderly. Factors such as growing geriatric population, increasing
awareness, rising focus on women health and, rising prevalence of cancer, poor
nutritional habits, rise in lactating and pregnant women in developing regions,
intestinal infections etc. are the major drivers for the market growth during
the forecast period. However, poor absorption of intravenous iron drugs and the
side effects associated with the treatment AND aplastic anemia treatment cost are the
restraining factors for the growth of the market during the forecast period.
The global Anemia Drugs Market is growing with
the sound pace. According to a recent study report published by the Market
Research Future, the global anemia drugs market is booming and is expected to
gain prominence over the forecast period growing rapidly. The market is
forecasted to demonstrate a spectacular growth by 2022, surpassing its previous
growth records in terms of value with a sound CAGR during the anticipated
period (2017 – 2022).
Global Anemia Drugs Market - Competitive Analysis
Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics
Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company
are some of the prominent players at the forefront of competition in the global
anemia drugs market and are profiled in MRFR Analysis.
Characterized by the presence of several well-established and small
players, the global anemia drugs market appears to be highly competitive and
fragmented. International players who are increasingly expanding their
footprint in the developing economies, makes it difficult for regional vendors
to compete with them, especially in terms of features such as product
portfolios, quality, and pricing. The market is witnessing intensified
competition which is expected to get more intensified further during the
forecast period. The intense competition prevalent in the market dictates the
consolidation among marketers.
Well established players incorporate acquisition, collaboration,
partnership, expansion, and product launch in order to gain competitive
advantage in this market and to maintain their market position.
In April-2017, Amgen Inc. expanded their commercial collaboration with
Novartis for erenumab, which is being investigated for the prevention of
migraine. This expanded commercial collaboration was built on a global
neuroscience collaboration in Alzheimer's disease and migraine established in
2015 between Novartis and Amgen. This expanded collaboration leveraged
Novartis' strong and established presence in neuroscience to more effectively
reach people with migraine.
In December-2015, GlaxoSmithKline plc. announced that its global HIV
business, ViiV Healthcare, has reached two separate agreements with
Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to
acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV
research assets.
In October-2016, Elanco U.S., Inc., a subsidiary of Eli Lilly and
Company acquired Boehringer Ingelheim Vetmedica, Inc.'s (BIVI) U.S. feline,
canine and rabies vaccines portfolio - as well as a fully integrated
manufacturing and R&D site - for USD 885 million, including the estimated
cost of acquired inventory.
Global Anemia Drugs Market - Regional Analysis
On the regional backgrounds the Americas leads the global market for
anemia drugs owing to huge patient population, increasing healthcare
expenditures and presence of the developed economies like U.S. and Canada
within the region. Following, the same trends Europe is second in the market.
The Asia Pacific region is the fastest growing region due to the developing
economies like India and China. Middle East and Africa have the least market
share, especially due to the presence of poor economies within the African
region. Moreover, stringent government policies within the region are
restraining the market growth within the region. On the hand, Middle East leads
the regional market due to the presence of developed economies like Kuwait,
Qatar, and others within the region and rising healthcare expenses.
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment